In patients with several tumor types, including melanoma, NSCLC, and bladder cancer, patients with TMB-H had better outcomes when treated with programmed death protein-1 and programmed cell death ligand-1 (PD-1/PD-L1) checkpoint inhibitors, or a cytotoxic T lymphocyte antigen 4 (CTLA-4) blockade [98,99,100]. The gene discussed is CD274; the disease is urinary bladder carcinoma.